Sun, Mar 1, 2015, 3:28 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Krispy Kreme Doughnuts, Inc. Message Board

letrob2000 3 posts  |  Last Activity: Feb 26, 2015 7:18 PM Member since: Jul 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Institutional Trading Alert for Johnson & Johnson

    Posted on 02/26/2015 by Edward Connelly

    A total of 22 block trades were executed today, typically at least 10,000 shares or more represent a single block unit. Block trades help investors understand the sentiment of large financial institutions. Further trading analysis reveals that 553.59K shares were bought and 224.81K shares were sold. The bought/sold ratio for shares of Johnson & Johnson is 2.46, representing a positive net cash flow of $33,681,888 into the stock.

    A deeper look into options trading also reveals that traders hedged their positions with options where 7.59K put and 22.29K call contracts exchanged hands leading to a 0.34 put/call ratio.
    Johnson & Johnson ranks as the world's largest and most diverse health-care company. The company comprises three divisions: pharmaceutical, medical devices and diagnostics, and consumer. While the pharmaceutical division currently represents close to 36% of total sales, we expect patent losses and the Synthes acquisition to reduce this proportion to approximately 27% during the next 10 years, with the device segment picking up the majority of the share.

    Johnson & Johnson settled the day up $1.59 to $102.80 in the previous trading session. Today's trading range was between $101.22 and $103.18 respectively. On the volume side, 11.18M shares were traded, which is greater than the average volume of 10.44M shares. JNJ is trading above the fifty day moving average and higher than the two hundred day moving average. The stock's 52 week low is $90.75 and 52 week high is $109.49. Within the last quarter, the shares have lost -5.51% of their value. The technical momentum Relative Strength Index indicator shows oversold conditions. The stock has a P/E ratio of 18.03 and a dividend yield of 0.70%.

    Sentiment: Strong Buy

  • letrob2000 letrob2000 Feb 26, 2015 7:12 PM Flag

    Outside the US, levosimendan is approved and marketed under the trade name of Simdax (levosimendan i.v.) in over 50 countries for use in Acute Decompensated Heart Failure. Over 800,000 patients have been prescribed the drug from its launch in early 2000.

    Mechanism of Action

    Levosimendan is a novel, first in class calcium sensitizer/K-ATP activator. The therapeutic effects of levosimendan are mediated through:
    •increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect which is not associated with substantial increases in oxygen demand (3).
    •opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds (4).
    •opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect (5)

    Low Cardiac Output Syndrome:Definition and Incidence

    LCOS is generally defined as a patient’s inability to maintain a cardiac index 2.2 L/min/m2 and hence requiring use of inotropic agents and/or mechanical assist devices such as an intra aortic balloon pump or a left ventricular assistance device. LCOS in the cardiac surgery setting is reported to occur in 5-10% of patients undergoing cardiac surgery and is associated with 10-15 fold higher mortality or severe sequelae as a result of poor organ perfusion (eg. kidney failure, end stage renal disease [ESRD]) (6),(7),(8),(9) (10).

    Patient Outcomes

    Post-cardiotomy LCOS is associated with poor outcomes including a 10- to 15-fold increase in operative mortality (9).

    Unmet Medical Need

    Currently no pharmacologic therapies are approved for management or prevention of post-cardiotomy LCOS. While conventional inotropes are used to manage cardiac hemodynamics in the peri-operative setting, none have been shown to improve outcomes.

    Sentiment: Buy

  • Did the U.S. Goverment Just Ensure Success for Apple Inc Pay?

    By Daniel B. Kline | More Articles
    February 22, 2015 | Comments (0)

    The Obama administration has given Apple (NASDAQ: AAPL ) Pay the presidential seal of approval.

    The White House announced earlier this month that Apple Pay will join EMV chip-and-PIN as a standard for the roughly 9 million federal payment cards, including debit card accounts, used for distributing Social Security and veterans benefits. Apple Pay allows people to make financial transactions using credit or debit card information stored on an iPhone or iPad.

    A press release from the White House detailed the steps taken: "Apple, Visa, MasterCard, Comerica Bank, and U.S. Bank are committed to working together to make Apple Pay, a tokenized, encrypted service, available for users of federal payment cards, including DirectExpress and GSA SmartPay cards."

    Apple Pay will also be accepted starting in September for some government transactions, CEO Tim Cook said on Feb. 13th while speaking at the White House Summit on Cybersecurity and Consumer Protection.

    These moves put Apple Pay on increasingly equal footing with traditional payment methods and should help the product gain traction.

    What does this mean?
    Allowing use of Apple Pay in government payments opens up a huge pool of business for the company. It could also serve as a litmus test to whether the general public will embrace mobile payments.

    "Tech and financial industries are hoping mobile payments will be the next big thing, but consumers really haven't seemed too interested so far," said Newsy's Zach Toombs in a video posted at USA Today. "So, there will likely be a lot of focus as to whether people embrace Apple Pay through the federal government."

    Once the new option is launched, Apple Pay will be an option for people receiving Social Security, veterans benefits, and other government money in lieu of the current system of prepaid debit cards. The opportunity for Apple, wh

    Sentiment: Strong Buy

21.82-0.28(-1.27%)Feb 27 4:07 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
PulteGroup, Inc.
NYSEFri, Feb 27, 2015 4:02 PM EST
Clean Energy Fuels Corp.
NASDAQFri, Feb 27, 2015 4:00 PM EST